TISSIUM, a cutting-edge medtech company specializing in biomorphic programmable polymers for tissue reconstruction, has successfully raised €50 million in a Series D funding round. The investment, supported by both new and returning international backers such as Fonds Stratégique des Transitions (ISALT) and Merieux Developpement, will finance TISSIUM’s commercial launch and platform expansion. The company is currently conducting a first-in-human study on its nerve repair product, COAPTIUM Connect, in Australia, says the company in a press release.
The funding will enable TISSIUM to commercialise its initial products for nerve and hernia repair, extend its product pipeline, and pursue international expansion. CEO Christophe Bancel expressed confidence in the company’s ability to enhance tissue reconstruction for patients and develop innovative solutions that improve lives.
A promising breakthrough
TISSIUM’s first nerve repair product, COAPTIUM Connect, is currently undergoing a first-in-human study in Australia. The trial marks a significant milestone in the company’s development, showcasing the potential of its biomorphic programmable polymers for tissue reconstruction. These innovative materials can be programmed to mimic the properties of human tissue, opening up new possibilities for nerve and hernia repair applications.
As the company moves closer to commercialising its first products, the Series D funding round will support its efforts in obtaining regulatory approvals and expanding its presence in the global medtech industry. With a strong emphasis on innovation, TISSIUM aims to make a real difference in patients’ lives by offering advanced solutions for tissue reconstruction challenges.
Expanding platforms and pursuing international expansion
The €50 million investment will enable TISSIUM to continue executing its development plan, including the commercialisation of its initial products in nerve and hernia repair, as well as extending its pipeline of products and platform. The company’s platform expansion will see it enter new therapeutic areas, driving further innovation in tissue reconstruction technology. This growth will be facilitated by leveraging in-house production, state-of-the-art manufacturing facilities, and strategic partnerships in certain verticals.
As TISSIUM pursues rapid international expansion, it will seek to establish a strong presence in the global medtech market, capitalising on its cutting-edge technology and unique approach to tissue reconstruction. The support of both new and existing investors, such as Fonds Stratégique des Transitions (ISALT), Merieux Developpement, Cathay Health, Credit Mutuel Innovation, and Sofinnova Partners, demonstrates confidence in the company’s potential to drive significant advancements in the field.